How to buy Caribou Bioscience stock (Caribou Bioscience)

Caribou Bioscience is a biotechnology business based in the US. Caribou Bioscience shares (CRBU) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.70 – a decrease of 5.56% over the previous week. Caribou Bioscience employs 158 staff and has a trailing 12-month revenue of around $11.5 million.

Our top picks for where to buy Caribou Biosciences stock

Buy Caribou Bioscience stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Caribou Bioscience stock price (NASDAQ: CRBU)

Use our graph to track the performance of CRBU stocks over time.

Caribou Bioscience shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$1.70
52-week range	$1.50 - $8.33
50-day moving average more info button	$2.07
200-day moving average more info button	$2.61
Wall St. target price	$12.50
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.66

Is it a good time to buy Caribou Bioscience stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Caribou Bioscience price performance over time

Historical closes compared with the close of $1.7 from 2024-12-26

1 week (2024-12-20)	-5.56%
1 month (2024-11-27)	-22.73%
3 months (2024-09-27)	-14.14%
6 months (2024-06-28)	3.66%

1 year (2023-12-28)	-71.09%
2 years (2022-12-28)	-69.48%
3 years (2021-12-28)	15.3
5 years (2019-12-24)	N/A

Caribou Bioscience financials

Revenue TTM	$11.5 million
Gross profit TTM	$-68,379,000
Return on assets TTM	-25.14%
Return on equity TTM	-43.6%
Profit margin	0%
Book value	$3.11
Market Capitalization more info button	$153 million

TTM: trailing 12 months

Caribou Bioscience share dividends

We're not expecting Caribou Bioscience to pay a dividend over the next 12 months.

You may also wish to consider:

Caribou Bioscience share price volatility

Over the last 12 months, Caribou Bioscience's shares have ranged in value from as little as $1.5 up to $8.33. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Caribou Bioscience's is 2.263. This would suggest that Caribou Bioscience's shares are significantly more volatile than the average for this exchange and represent a higher risk.

To put Caribou Bioscience's beta into context you can compare it against those of similar companies.

• Intellia Therapeutics (NTLA.US): 1.806
• Editas Medicine (EDIT.US): 2.006
• Crispr Therapeutics (CRSP.US): 1.662

Caribou Bioscience overview

Caribou Biosciences, Inc. , a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California. .

Frequently asked questions

null
What percentage of Caribou Bioscience is owned by insiders or institutions?
Currently 10.037% of Caribou Bioscience shares are held by insiders and 62.487% by institutions. How many people work for Caribou Bioscience?
Latest data suggests 158 work at Caribou Bioscience. When does the fiscal year end for Caribou Bioscience?
Caribou Bioscience's fiscal year ends in December. Where is Caribou Bioscience based?
Caribou Bioscience's address is: 2929 7th Street, Berkeley, CA, United States, 94710 What is Caribou Bioscience's ISIN number?
Caribou Bioscience's international securities identification number is: US1420381089